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Key point summary 
 
 Information describing alterations in vascular function during either acute or prolonged 
normobaric or hypobaric hypoxia is sparse and often confounded by pathology and 
methodological limitations. 
 
 We show that high altitude exposure in lowlanders is associated with impairments in both 
endothelial and smooth muscle function, and with increased central arterial stiffness. 
Furthermore, in all of these respects, lowlanders’ vasculature becomes comparable to that 
of natives born and raised at altitude.  
 
 Changes in endothelial function occur very rapidly in normobaric hypoxia, and partly 
under the influence of sympathetic nerve activity. 
 
 Thus, a lifetime of high altitude exposure neither attenuates nor intensifies the 
impairments in vascular function observed with short-term exposure in lowlanders; such 
impairment and altered structure likely translate into an elevated cardiovascular risk.  
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Abstract 
Research detailing the normal vascular adaptions to high altitude is minimal and often 
confounded by pathology (e.g., chronic mountain sickness) and methodological issues. We 
examined vascular function and structure in: 1) Healthy lowlanders during acute hypoxia and 
prolonged (~2 weeks) exposure to high altitude, and 2) High-altitude natives at 5050 m 
(highlanders). In 12 healthy lowlanders (aged 32±7 y) and 12 highlanders (Sherpa; 33±14 y) we 
assessed brachial endothelium-dependent flow mediated dilation (FMD), endothelium-
independent dilation (via glyceryl trinitrate; GTN), common carotid intima thickness (CIMT) 
and diameter (ultrasound), and arterial stiffness via pulse wave velocity (PWV; applanation 
tonometry). Cephalic venous biomarkers of free radical-mediated lipid peroxidation (lipid 
hydroperoxides, LOOH), nitrite (NO
2
) and lipid soluble antioxidants were also obtained at rest. 
In lowlanders, measurements were performed at sea level (334 m) and between days 3-4 (acute 
high altitude) and 12-14 (chronic high altitude) following arrival to 5050 m. Highlander were 
assessed once at 5050 m. Compared with sea level, acute high altitude reduced lowlanders’ FMD 
(7.9 ± 0.4 vs. 6.8 ± 0.4%; P=0.004) and GTN-dilation (16.6 ± 0.9 vs. 14.5 ± 0.8%; P=0.006), and 
raised central-PWV (6.0 ± 0.2 vs. 6.6 ± 0.3 m/s; P=0.001). These changes persisted at days 12-
14, and after allometrically scaling FMD to adjust for altered baseline diameter. Compared to 
lowlanders at sea level and high altitude, highlanders had a lower carotid wall: lumen ratio 
(~19%, P≤0.04), attributable to a narrower CIMT and wider lumen. Although both LOOH and 
NO
2
 increased with high altitude in lowlanders, only LOOH correlated with the reduction in 
GTN-induced dilation evident during acute (n=11, r=-0.53) and chronic (n=7, r=-0.69; P≤0.01) 
exposure to 5050 m. In a follow-up, placebo-controlled experiment (n=11 healthy lowlanders) 
conducted in a normobaric hypoxic chamber (FIO2=0.11; 6 h), a sustained reduction in FMD was 
evident within 1 hr of hypoxic exposure when compared to normoxic baseline (5.7 ±1.6 vs. 8.0 
±1.3%; P<0.01); this decline in FMD was largely reversed following α1-adrenoreceptor 
blockade. In conclusion, high-altitude exposure in lowlanders caused persistent impairment in 
vascular function, which was mediated partially via oxidative stress and sympathoexcitation. 
Although a lifetime of high altitude exposure neither intensifies nor attenuates the impairments 
seen with short-term exposure, chronic high altitude exposure appears to be associated with 
arterial remodeling.  
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Introduction  
Ambient hypoxia associated with high altitude is a potent activator of the sympathetic nervous 
system (Saito et al., 1988; Marshall, 1994; Duplain et al., 1999; Xie et al., 2001; Hansen & 
Sander, 2003), which causes vascular dysfunction (Hijmering et al., 2002). Indeed, intermittent 
or sustained hypoxia in pathologies such as sleep apnoea, have been associated with vascular 
dysfunction (Lurie, 2011; Phillips et al., 2013). However, information describing alterations in 
vascular function during either acute or prolonged exposure to high altitude is sparse and often 
confounded by pathology (i.e. acute / chronic mountain stickiness, metabolic syndrome) and 
methodological issues. Previously, acute exposure to high altitude (3,450 m and 4,770 m) has 
been reported to  impair endothelial function (Rhodes et al., 2011). However, these conclusions 
were based on measurements derived from finger photoplethysmography and derived estimates 
of changes in arterial stiffness and tone, rather than the more direct and widely adopted non-
invasive measures of pulse-wave velocity (PWV; a measure of arterial stiffness (Laurent et al., 
2006)) and endothelium flow-mediated dilatation (FMD; as a measure of vascular function 
(Corretti et al., 2002; Green, 2005)).  
Frick et al. (2006) assessed endothelial-dependent FMD following acute (1 day) and prolonged 
(3 week) exposure to a moderate altitude (1,700 m) in individuals with the metabolic syndrome. 
Endothelial-dependent FMD was unchanged during acute exposure but impaired following the 
prolonged exposure (despite participation in an exercise intervention over this period). However, 
methodological issues existed which cloud interpretation of those data, including: lack of a 
control group; uncertain non standardisation of cuff placement during the FMD assessment, and 
lack of continuous monitoring of artery diameter and blood flow during reactive hyperaemia 
(Thijssen et al., 2011). Specifically, the lack of continuous monitoring of artery diameter and 
blood flow can result in measurement error, and the true peak response may have been missed 
(Black et al., 2008). Furthermore, 1700 m is a relatively weak hypoxic stimulus relative to 
altitudes that are readily accessed or lived in by many, thus the potential negative effect of high-
altitude exposure on vascular function and structure in lowlanders, especially in a non-diseased 
population has not been adequately established. 
Impairments in brachial vascular function and structure have been recently documented in native 
Andean highlanders, with chronic mountain sickness (Rimoldi et al., 2012; Bailey et al., 2013). 
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Despite elevated levels of oxidative stress, endothelial-dependent FMD in the highlanders free 
from chronic mountain sickness was found to be comparable to healthy lowlanders at sea level 
(Rimoldi et al., 2012). Yet, healthy lowlanders exposed to acute normobaric hypoxia exhibited 
vascular dysfunction, based on indirect biomarkers of oxidative stress (Bailey et al., 2013). 
Whilst the research findings of Rimoldi et al. (2012) and Bailey et al. (2013) are relevant to 
chronic mountain sickness, vascular function in healthy lowlanders travelling from sea level to 
high altitude has not been comprehensively examined, nor compared with permanent high-
altitude residents. The latter is of particular interest given that native highlanders have been 
reported to show earlier cardiovascular degeneration changes with ageing, in particular arterial 
wall stiffening (Otsuka et al., 2005). 
We therefore aimed to 1) Examine potential alterations in vascular function and structure in 
healthy lowlanders following initial ascent and ~2 weeks of acclimatisation to high altitude 
(5050 m), and 2) Examine the potential effect of chronic exposure to hypoxia on vascular 
function and structure in native Sherpa’s (highlanders) born and permanently residing at high 
altitude. We hypothesised that: 1) Lowlanders’ endothelial-dependent FMD and arterial stiffness 
would be impaired following acute exposure to high altitude, and further impairments would be 
evident following a more chronic stay at high altitude; 2) Measures of vascular function and 
structure in highlanders would be comparable to lowlanders at sea level; however, following ~2 
weeks of high-altitude exposure, measures of vascular function and structure would be impaired 
in lowlanders compared to highlanders. To provide some mechanistic insight into potential 
alterations in vascular function, hypoxic-mediated alterations in systemic oxidative stress, nitrite 
(NO 2 ) and antioxidants were also quantified from plasma samples. It was anticipated that 
increased oxidative stress and concomitant reductions in NO
2
at high altitude would be related to 
impairments in vascular function.  
In addition, based on the findings from this study (study 1) we conducted a follow-up study 
(study 2) to gain further insight on the mechanisms and time-course changes in the FMD 
response during acute hypoxic exposure. An increase in sympathetic outflow has previously been 
shown to attenuate FMD by ~57% (relative), yet this attenuation was completely abolished by 
alpha (α)-adrenergic blockade (Hijmering et al., 2002). We reasoned that the FMD impairment 
seen with high altitude might also have been mediated via elevations in sympathetic nerve 
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activity via an α-adrenergic mechanism; therefore, blocking the hypoxic-induced elevations in 
sympathetic nerve activity may potentially restore FMD. To address this possibility, we 
conducted a placebo-controlled experiment (study 2; n=11) in a normobaric hypoxic chamber 
(FIO2=~0.11; ~6 h) following selective α1 -sympathetic receptor blockade (1 mg/20 kg body 
mass; prazosin). We hypothesised that: 1) FMD would be progressively impaired in normobaric 
hypoxia, and 2) α1-adrenergic blockade would partially normalize the hypoxic-induced 
reductions in FMD.  
 
Methods  
Ethical approval 
Study 1 and 2 were approved by the Human Ethics Committee of the University of British 
Columbia and the Nepal Health Medical Research Council, and conformed to the standards set 
by the Declaration of Helsinki. Verbal and or written consent was obtained by all participants. 
Sea-level experiments took place at the University of British Columbia, Okanagan (344 m; 
barometric pressure 755 ± 7 mm Hg) while high-altitude experiments were conducted at the Ev-
K2-CNR Pyramid Laboratory in the Khumbu Valley in Nepal (5050 m; barometric pressure 413 
± 1 mm Hg).  
Study 1 - high altitude 
Participants 
Lowlanders: Twelve healthy normotensive volunteers (10 males; 2 females) with a mean ± SD 
age of 32 ± 7 yrs, body mass 76 ± 13 kg, height 176 ± 7 cm and body mass index 25 ± 4  kg/m
2
, 
were recruited for this experiment. Participants were non-smokers, had no previous history of 
cardiovascular, cerebrovascular or respiratory diseases, and were not taking any cardiovascular 
medications. All participants were born and lived close to sea level (<1000 m) and none had 
been to high altitude for >2 years.  
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Highlanders: Following informed consent, twelve male natives Sherpa’s (33 ± 14 yrs; body mass 
69 ± 16 kg, height 170 ± 8 cm, body mass index 24 ± 5 kg/m
2
) were screened through Nepalese 
translation by a medical practitioner, and had no known previous history of cardiovascular, 
cerebrovascular or respiratory diseases, nor were they taking any cardiovascular medications. All 
participants were born and permanently residing at high altitude between 3440 m – 6119 m 
(mean ± SD: 4372 ± 673 m).  
 
Design and ascent protocol 
Following screening and familiarisation with the experimental procedures, lowland participants 
underwent the experimental session at sea level, upon initial arrival at high altitude (between 
days 3 and 4; acute-high altitude) and following 12-14 days of acclimatisation (chronic-high 
altitude; see figure 1), while the highlander group completed one session at high altitude (5050 
m) only (testing procedures were identical except for brachial artery vasodilator capacity test, see 
below). Lowland participants spent 6 days at Kathmandu (1400 m) before flying to Lukla (2860 
m). Participants then trekked to the Ev-K2-CNR Pyramid Laboratory over a 9-11-day period, 
which included rest days at Namche Bazar (3450 m), Pangboche (3985 m) and Pheriche (4371 
m). Arrival at 5050 m for the lowland group was staggered to facilitate measures within the 
desired time course across the two weeks, consequentially, participants arrived at 5050 m after 
spending 1 (n=6), 2 (n=4) or 3 (n=2) rest days at 4371 m. Participants were given low-dose 
acetazolamide (125 mg bd) for the first 7 days of ascent to minimise acute mountain sickness 
prophylaxis, as recommended (Basnyat et al., 2006). Importantly, treatment was discontinued on 
day 8 to allow for sufficient clearance time (i.e., >48 h) (Ritschel et al., 1998). Experimental 
testing began after 12-h abstinence from alcohol, caffeine, and strenuous exercise, and a 4-h fast. 
This study was part of a larger research expedition and consequently participants took part in a 
number of studies conducted during 3 weeks at the Pyramid Laboratory. The recovery time 
between the various testing sessions was managed to prevent any potential for confounding 
results (e.g., >48 hours between all drug and/or exercise intervention studies). 
 
Measurements  
All measures were made following a minimum of 15 min of supine rest. Arterial oxygen 
saturation (SaO2) was monitored via pulse oximetry (Pulse Oximeter MD300K1; Vacumed, 
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Canada). Continuous beat-to-beat measures of arterial blood pressure (BP; finger 
photoplethysmography; Finapres Medical Systems, Biomedical Instruments, The Netherlands) 
and heart rate (HR, 3-lead ECG; ML132, ADInstruments, Colorado Springs CO, USA) were 
recorded. Manual sphygmomanometer BP recordings were obtained during supine rest to 
confirm the accuracy of the finger photoplethysmography measurements. All data were sampled 
continuously using an analogue-digital converter (PowerLab/4S ML750; ADInstruments) 
interfaced with a computer and displayed in real time during testing. Data were stored for 
subsequent off-line analysis using the commercially available software (Chart v7, 
ADInstruments). All tests were completed in the following order: 
 
Arterial stiffness: Adhering to the international guidelines (Laurent et al., 2006), hand held-
tonometry (SPT-301 Millar Instruments, Houston, Texas) was employed to assess central 
(carotid-femoral PWV) and peripheral (carotid-radial PWV) arterial stiffness. Twenty 
reproducible carotid-femoral artery waveforms and 20 separate carotid-radial artery waveforms 
were recorded simultaneously using mechanotransducers, which were applied directly to the skin 
and over the area of greatest pulsation. The distance from the 4
th
 intercostal space in the midline 
of the sternum to the individual carotid, femoral and radial artery pulse sites were measured 
along the surface of the body using a measuring tape. This technique was used as it has been 
shown to have the best agreement with aortic PWV measured invasively using cardiac 
catheterization (Weber et al., 2009). The foot to foot method was used to determine pulse transit 
time, using a bandpass filter (5-30 Hz) to identify the foot or “notch” of the carotid-femoral and -
radial waveform, and the difference in time from R interval to systolic upstroke at each location. 
Pulse distance was determined by subtracting the distance from carotid measurement to the 
sternal notch from the distance from the sternal notch to the femoral and radial pulse site 
measurement. Pulse-wave velocity was then determined by dividing distance by pulse transit 
time. The day-to-day intra-observer coefficient variation (CV) for central and peripheral PWV 
(n=6) was 4.8% and 4.7%, respectively (Lewis et al., unpublished observations). 
 
Local artery stiffness in the common carotid artery (CCA) was also assessed. Carotid ultrasound 
images and carotid BP were collected simultaneously over 20-30 cardiac cycles. Left CCA BP 
waveforms, a representative of carotid arterial pressure, were obtained using the hand-held 
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tonometer positioned over the greatest pulsation. Right CCA ultrasound images were obtained 
~1-2 cm proximal to the bifurcation of the external and internal carotid arteries using a 10-MHz 
multifrequency linear array probe, attached to a B-mode high-resolution ultrasound machine 
[Terason 3000TM, Teratech, Burlington, MA, USA]. Maximal and minimal lumen diameters 
were calculated using edge-detection software (described below). Ten carotid and brachial 
waveforms along with 10 complete cardiac cycles of carotid diameter change were averaged, and 
carotid arterial compliance, distensibility and ß-stiffness index were calculated (Tanaka et al., 
2000) (Figure 2).  
Carotid Intima-Medial Thickness (CIMT): The right carotid artery was imaged in the 
anterolateral, posterolateral and mediolateral planes, 1-2 cm proximal to the carotid bulb (Stein 
et al., 2008), using a high-resolution ultrasound machine (Vivid-q, GE, Fairfield, CT, USA) 
attached to an 8L-RS MHz high frequency linear array transducer. Participants were measured in 
the supine position with a slight hyperextension of the neck at a 45° angle. The CIMT at end-
diastole (1 frame prior to the R-interval) of 10 successive beats were recorded at each of the 
three angles and averaged. All analysis was completed offline using commercial edge-detection 
software (EchoPAC PC, GE Healthcare; Figure 2). To correct for differences in diameter, we 
also calculated the wall-to-lumen ratio. 
Brachial artery vascular function: A 10-MHz multifrequency linear array probe attached to a 
high-resolution ultrasound machine (Terason 3000
TM
, Teratech) was used to image the brachial 
artery in the right arm during the three tests employed to examine brachial vascular function:  
 
Endothelium-dependent FMD: FMD was assessed according to international guidelines (Black et 
al., 2008). With the occluding cuff placed distal to the ultrasound probe, 1 min of diameter and 
flow recordings preceded forearm cuff inflation (>200 mm Hg) for 5 min. Diameter and flow 
recordings resumed 30 s prior to cuff deflation and continued for 3 min thereafter. In the current 
study the day-to-day intra-observer CV for FMD was 3.6% (n=6; Lewis et al., unpublished 
observations). 
 
Brachial artery vasodilator capacity:  Following a 10-min resting period, the occluding cuff was 
positioned above the imaged part of the brachial artery, i.e., proximally on the upper arm. 
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Following 1 min of diameter and velocity recordings, the cuff was inflated (>200 mm Hg) for 5 
min. During the middle 3 min of cuff occlusion, ischaemic handgrip exercise was performed. 
Diameter and flow recordings resumed 30 s prior to cuff deflation and continued for 3 min 
thereafter. This protocol results in a near-maximal dilatation of the brachial artery in humans and 
provides a valid index of peak vasodilator capacity (Tinken et al., 2008). In the current study the 
day-to-day intra-observer CV was 6.7% (n=6; Lewis et al., unpublished observations).  
 
Endothelium-independent FMD (GTN): Following 10 min of rest, brachial diameter and velocity 
were recorded for 1 min. Participants then received a sublingual dose of glyceryl trinitrate (GTN; 
400 µg spray). Diameter and flow recordings were taken continuously for a 10-min period 
thereafter. 
 
Metabolic measurements: In lowlanders only, venous blood was obtained without stasis from a 
forearm antecubital vein after at least 20 min of supine rest, at sea level (n=11) as well as one 
day (n=11) and one week (n=7) after arrival at high altitude. Blood was collected into EDTA and 
serum vaccutainers. EDTA-plasma was drawn after centrifugation (3000 rpm at 4 °C) for 10 min 
and serum was drawn after leaving vaccutainers at room temperature for 60 min prior to 
centrifugation. Plasma and serum were placed in a -80 °C freezer at sea level, or -40 °C freezer 
at high altitude, for up to 10 days where they remained frozen during transport on dry-ice to the 
UK prior to batch analysis. 
 
Biomarkers of oxidative stress and NO bioavailability:  
Antioxidants: Plasma /γ-tocopherol, /β-carotene, retinol, lycopene, zexanthin, β-cryptoxanthin 
and lutein were determined using an HPLC method (Catignani & Bieri, 1983; Thurnham et al., 
1988). The intra and inter-assay CV were both <5%. 
Lipid hydroperoxides (LOOH): Serum LOOH was determined using the ferrous iron/xylenol 
orange assay (Wolff, 1994) with modification.  The intra/inter-assay CV were both <5%. 
 
Nitrite (NO 2 ): Plasma NO 2
 
was measured via ozone-based chemiluminescence (OBC Model 
280i, NOA
®
, Sievers, Boulder, CO, USA) following reduction by potassium iodide in acetic acid 
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according to established methods (Pelletier et al., 2006). The intra and inter-assay CV were both 
<5%. 
Study 2 - Normobaric hypoxia and α1-adrenoreceptor blockade 
Eleven healthy normotensive volunteers (7 males: 4 females) with a mean (± SD) age of 24 ± 3 
years, body mass 75 ± 10 kg, height 174 ± 6 cm and body mass index 25 ± 3 kg/m
2
, participated 
in this randomized placebo-controlled experiment. Experimental sessions commenced between 
08:00 and 09:00 hrs and measurements of FMD, SaO2 and BP (as described above) were made in 
normoxia and during normobaric hypoxia (FIO2=0.11) at 60 min, 210 min and 330 min, and then 
60 min after returning to normobaric normoxia (Figure 1). This level of hypoxia was chosen as it 
equivalent to an altitude of 5,000 m. Participants ingested the α1-adrenoreceptor blocker, 
prazosin (1 mg/20 kg body mass) or an identical placebo capsule 90 min before the last 
assessment in hypoxia. Prazosin has been shown to induce systemic peripheral arterial-dilation 
and venodilation via the removal of sympathetic nerve activity (Awan et al., 1977; Jauernig et 
al., 1978). This clinically-acceptable dose of prazosin has previously been shown to have a 
functional block of ~80% and peak activity 90- to 180-min post-ingestion (Ogoh et al., 2008; 
Jones et al., 2011; Lewis et al., 2012, 2013).  Each experiment was separated by ≥ 7 days, and a 
small standardised snack and 250 mL of water were provided following each FMD assessment.  
 
Data Analysis 
Calculations: Baseline measures of BP and HR were averaged over 1 min following 15-min 
supine rest. Custom-designed edge-detection and wall-tracking software, which is largely 
independent of investigator bias, was utilised for the analysis of CCA and brachial diameter and 
brachial blood flow velocity [(Woodman et al., 2001; Black et al., 2008) see Figure 2]. This 
software provides continuous and simultaneous diameter, velocity and shear rate (SR; 4 x 
velocity / diameter) measurements, as well as post hoc calculation of FMD, vasodilator capacity 
and GTN responses. This semi-automated software provides higher reproducibility of diameter 
measurements and reduces both observer error and bias with a reported intra-observer CV for 
FMD% of 6.7% (Woodman et al., 2001). Data are presented as absolute (millimetres) and 
relative (percentage) rises from the preceding baseline diameter and are calculated based on 
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standardised algorithms applied by the software (Black et al., 2008). In accordance with 
procedural recommendations (Pyke & Tschakovsky, 2005, 2007; Atkinson et al., 2009), we also 
measured the post-deflation area under the shear rate curve in order to best interpret any changes 
in FMD. Recent evidence has highlighted that the general use of FMD% is associated with 
statistical bias as it may fail to consider the difference in baseline artery diameter following an 
intervention or between groups (Atkinson & Batterham, 2013; Atkinson et al., 2013). Therefore, 
using recent guidelines that provide a statistical quantification of FMD, which is independent of 
baseline artery size (Atkinson & Batterham, 2013; Atkinson et al., 2013); we adopted an 
allometric scaling approach to adjust for variability in baseline diameter. These results are 
presented as “corrected” FMD %. This approach is reported to improve the specificity and 
interpretation of the FMD protocol (Atkinson & Batterham, 2013; Atkinson et al., 2013) and is 
used herein as a complementary measure of vascular function.  
 
Statistical analysis: All data were analysed using SPSS (version 21, IBM, Surrey, UK) and 
expressed as mean ± SD. Statistical significance was defined as P≤0.05 and distribution 
normality confirmed using repeated Shapiro-Wilk W tests. Study 1: Trial differences within 
lowlanders between sea-level, initial-high altitude and prolonged-high altitude were analysed 
using a one-way repeated measures ANOVA. Pearson’s correlation analysis was used to 
examine the relationship between measures. Difference between highlanders and lowlanders at 
were explored using independent t-tests. Study 2: The time course changes of hypoxia in the 
placebo trial were examined using one-way repeated measures ANOVA, to establish the effect of 
the hypoxic stimulus on FMD. To examine the interaction between the time course change and 
experimental condition (placebo vs. α1-blockade) a two-way repeated measures ANOVA was 
used; to further exposure any significant interaction effect, paired t-tests were used to exposure 
the effect of the α1-blockade on the vascular changes with hypoxia.  
 
Results 
Study 1 
Lowlanders at high altitude: Arterial oxygen saturation was markedly lower and HR was 
significantly higher following acute-high altitude (-18 ± 2% and +21 ± 4 beats∙min-1, 
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respectively; P<0.001) and chronic prolonged-high altitude exposure (-16 ± 3% and +18 ± 4 
beats∙min-1; P<0.001; Table 1) compared with sea level. Arterial blood pressure, CIMT, CCA 
pulse pressure, CCA distensibilty, CCA wall: lumen ratio, and β-stiffness were unaltered with 
high-altitude exposure (Table 1; Figure 3).  
Compared to sea level, central-PWV was greater following acute-high altitude (9%; +0.6 ± 0.06 
m∙s-1; P=0.04) and even more so following chronic-high altitude exposure (13%; +0.8 ± -0.1 m∙s-
1
; P=0.006; Figure 4). No difference in peripheral-PWV was evident with high-altitude exposure 
(n=11; Figure 4). Compared to sea level, carotid compliance was higher following initial arrival 
to high altitude (by 0.05 ± -0.01 mm
2∙mm Hg; P=0.006); however, this difference was not 
evident following ~2 weeks of high-altitude exposure (Table 1). Both systolic and diastolic 
diameter of the CCA increased with acute exposure to high altitude, and remained so following 
chronic exposure (~0.5 mm; P≤0.007; Figure 3).  
Compared with sea level, brachial FMD and GTN were reduced by 1.1 ± 0.1% (relative change 
~14%) and 2.4 ± 1.6% (relative ~14%), respectively (P≤0.02; Figure 5) following acute altitude 
exposure. Following ~2 weeks at high altitude, both FMD and GTN remained reduced when 
compared with sea level, by 0.6 ± 0.6% (relative 8%; P=0.01) and 1.8 ± 2.1% (relative 
11%;P=0.06), respectively (Figure 5). Compared with sea level, vasodilator capacity (n=11) 
displayed a trend towards being reduced (P=0.07) by 1.8 ± 2.4 (relative ~14%) and 1.0 ± 2.4 
(relative ~8%) following initial arrival to altitude and following ~2 weeks, respectively. 
Compared with initial arrival to 5050 m, FMD shear rate area under the curve was lower 
following ~2 weeks at altitude (by 81,568 ± 3,856 AUC , P=0.03; Table 1), while no other 
differences were evident across the time spent at 5050 m (Table 1). Compared to sea level, 
allometrically “corrected” FMD was also reduced by 1.2 ± 0% (relative ~15%) and 0.6 ± 0% 
(relative ~8%) following acute and chronic  high altitude exposures, respectively (P≤0.03; Table 
1).  
Markers of oxidative stress and NO bioavailability: Serum LOOH and plasma NO 2  increased in 
lowlanders following acute high-altitude exposure, by 17% (P=0.01) and 72% (P=0.06), 
respectively (see Table 2). A significant negative correlation between LOOH and GTN-induced 
dilation was evident for initial arrival (n=11, r=-0.53; P=0.01) and chronic exposure (n=7, r=-
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0.69; P≤0.001); according to the coefficient of determination, elevations in LOOH statistically 
accounted for 28% and 48% of the decrease in GTN with acute- and chronic-high altitude 
exposure, respectively. Although significance was not reached, a trend for a positive correlation 
between LOOH and central arterial stiffness was also evident following initial arrival to 5050 m 
(r=+0.39; P=0.07). No other correlations were evident. Plasma retinol following initial arrive to 
5050m, showed a 9% increase from sea level; the concentration of the other measured lipid 
soluble antioxidants were significantly unaltered with high altitude exposure (Table 2). 
 
Comparison between lowlanders and native highlanders: Compared with lowlanders at sea level, 
highlanders  had lower mean arterial blood pressure (-10 ± 2 mm Hg; P=0.03), SaO2 (-16 ± 1%; 
P<0.001), CCA pulse pressure (-8 ± 4 mm Hg; P=0.04), and a higher HR (+21 ± 1 beats∙min-1; 
P<0.001) and central-PWV (17%; +1.0 ± 0.7 m∙s-1; P=0.05; Figure 4); however, once lowlanders 
were exposed to high altitude these between-group differences were not present (Table 1, Figure 
4). Compared with lowlanders at sea level, highlanders systolic and diastolic CCA diameters 
were larger (11%; +0.7 ± 0.1 mm and +0.8 ± 0.2 mm, respectively; P≤0.005; Figure 3), and both 
FMD and GTN dilation displayed a trend of being reduced by 1.6 ± 3.0% (relative ~20%; 
P<0.10) and 3.5 ± 4.7% (relative ~ 21%; P=0.07; Figure 5). However, again these between-group 
differences were absent when lowlanders were exposed to high altitude. In contrast, highlander’s 
wall: lumen ratio was ~19% lower when compared to lowlanders at both sea level and at high 
altitude (P≤0.04; Figure 3). 
 
Study 2 - Normobaric hypoxia and α1-adrenoreceptor blockade 
Time course alterations to hypoxia within the placebo trial: Compared to normoxic baseline (0 
min) SaO2 was reduced and HR was elevated during hypoxic exposure (Table 3). Due to 
technical issues (i.e. loss of one recording), FMD time course related data within the placebo trial 
were obtained in 10 out of the 11 participants.  Compared to normoxic baseline, FMD was 
reduced following 60 min, 210, and 330 min of hypoxia by 1.6 ± 0.2 % (relative 28%), 2.5 ± 0.1 
% and  2.8 ± 0.2 % (relative 36%), respectively (P≤0.003; Figure 6). Although no significant 
difference was evident between normoxic conditions (baseline and 60-min post-hypoxia 
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recovery), FMD was 1.3 ± 0.2 % (relative 16%) higher in normoxic recovery from hypoxia 
exposure.  
The effect of the α1-adrenoreceptor blockade: Two-way repeated measures ANOVA (n=9) 
revealed a significant interaction between time and condition for HR and FMD. Pair t-test 
analysis revealed that compared to the placebo trial, HR and FMD were 5 ± 2 beats∙min-1 
(P=0.03; Table 3) and 1.8 ± 1.4 % (relative 35%; P=0.002; Figure 6) higher following α1-
adrenoreceptor blockade after 330 min of hypoxic exposure. 
 
Discussion  
This is the first study to comprehensively examine the time course and potential mechanisms of 
alterations in vascular function and structure in healthy lowland individuals during normobaric 
hypoxia, upon ascent to and following a partial acclimatization to high altitude, and to provide 
relevant comparisons with high-altitude natives. Acute exposure to 5050 m in lowlanders was 
associated with an impairment in both endothelial-dependent (FMD) and endothelial-
independent (GTN) dilatation, and an increase in central-PWV and CCA diameter. These 
changes were neither exacerbated nor resolved with chronic-high altitude exposure. Compared to 
lowlanders at sea level, highlanders had a lower FMD and GTN dilation response, a higher 
central-PWV and a larger CCA diameter. These between-group differences were removed when 
lowlanders were exposed to 5050 m, with only one exception (carotid wall: lumen ratio). In 
lowlanders, we found that alterations in elevations in oxidative stress were partially and 
selectively related to the reductions in GTN-induced vasodilation at 5050 m. In a follow-up 
placebo-controlled experiment conducted in a normobaric hypoxic chamber, we found that 
sustained reductions (-28-36%) in FMD occur within 60 min and could be partially reversed 
following α1-adrenoreceptor blockade. We conclude that high altitude exposure in lowlanders 
was associated with persistent impairment in vascular function, and was potentially mediated via 
oxidative stress and sympathoexcitation. Although a lifetime of high-altitude exposure does not 
intensify the observed vascular function impairments seen with acute exposure, chronic high-
altitude exposure appears to be associated with altered arterial structure; whether this is an 
adaptive or maladaptive response remains to be established.     
17 
 
 
Influence of high altitude on vascular structure and function in lowlanders: Flow mediated 
dilation, an index of cardiovascular risk(Mullen et al., 2001; Green et al., 2005; Green et al., 
2012; Maruhashi et al., 2013), was reduced by 14% in healthy lowlanders upon initial exposure 
to 5050  m, and did not change following ~2 weeks at this elevation. These findings contrast 
with those reported by Frick et al. (2006), where FMD following 3 weeks at 1700 m was reduced 
by ~49%. However, given the methodological issues discussed above, comparison with this 
study is difficult. Given the comparable brachial baseline diameter and FMD shear stress 
between sea level and arrival to high altitude, the initial reduction in FMD with high altitude 
does not appear to be explained by alterations in diameter or the shear stress stimulus on the 
vessel. Moreover, our findings persisted following allometric scaling to control for variability in 
baseline diameter and therefore, improved specificity and interpretation of the FMD protocol 
(Atkinson & Batterham, 2013; Atkinson et al., 2013).  
We also quantified the peak vasodilatory capacity of the brachial artery, and found this too was 
reduced by 14% at high altitude. This measure is a valid index and surrogate measure for arterial 
structural remodelling (Naylor et al. 2005). The artery dilation associated with the assessment of 
vasodilator capacity in the current study is less dependent on NO than the FMD assessment. For 
example, it has previously been shown that when cuff occlusion is proximal to the site of 
vascular imaging (as used in the current study for testing vasodilator capacity), NO accounts for 
only 40% of the dilation response (Doshi et al., 2001; Green et al., 2012); the degree of shear 
stress and release of multiple vasoactive substances contribute to the additional artery dilation 
(Green et al., 2012). It would seem that a balance of NO and other vasoactive substances, in 
addition to neurogenic factors, underpin the vascular changes observed at high altitude, and are 
considered below.  
 
Potential mechanisms of action for initial reduction in FMD: A positive relationship between 
SaO2 and FMD (r=0.62) has previously been reported, and 100% oxygen inhalation has been 
shown to improve FMD in hypoxemic (SaO2 <90%), but not in normoxemic (SaO2 <90%) 
control participants, suggesting that vascular dysfunction to high altitude, is partly influenced by 
hypoxemia (Rimoldi et al., 2012). In the current study, a similar weak-to-moderate relationship 
was evident between FMD and SaO2 (r=0.33, P=0.05), and calculation of the coefficient of 
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determination indicates that the change in SaO2 potentially explained around 11% of the change 
in FMD; confirming the multifactorial nature of vascular dysfunction and that other 
mechanism(s) are involved in the impairment of FMD at high altitude.  
 
In contrast to our hypothesis, and previous findings (Frick et al., 2006), GTN-induced dilation in 
lowlanders was also reduced at both time points at high altitude. It is accepted that GTN-induced 
dilation provides an index of the maximum obtainable vasodilator response, and represents 
vascular smooth muscle function (Corretti et al., 2002; Maruhashi et al., 2013). This particular 
assessment is used as a control test for FMD measures, as the assessment of FMD is based on the 
premise that endothelium-independent dilation is not altered, and any alterations seen in FMD 
measures is resultant of endothelial dysfunction, and not vascular smooth muscle 
dysfunction(Maruhashi et al., 2013). Given that GTN-dilation and FMD were each reduced by 
~14% with acute exposure to 5050 m, these findings indicate that alterations in vascular smooth 
muscle function and/or structure contributed to the decline in FMD at high altitude. The potential 
mechanism(s) by which ambient hypoxia alters vascular smooth muscle function/structure is 
unknown. Endothelial dysfunction associated with acute hypoxia at sea level, has been 
associated with a reduced NO-bioavailability in both humans (Cosby et al., 2003; Maher et al., 
2008) and rodents (Reboul et al., 2005; Hernandez-Guerra et al., 2013); however, in agreement 
with others (Janocha et al., 2011; Beall et al., 2012) we found that vascular NO bioavailability 
(as indexed by plasma NO
2
) increased with high altitude. Thus, it seems that vascular 
dysfunction clearly cannot be explained by reduced NO bioavailability per se, but is more likely 
related to additional factors including the direct vasculo-toxic/constrictive effects of elevations in 
LOOH, as confirmed by the observed correlation. Consistent with these findings, there is 
evidence to indicate that hypoxic upregulation of superoxide production (Dweik, 2005) 
potentially hinders the intravascular signalling processes in smooth muscle cells required for 
relaxation (e.g., soluble guanylyl cyclase and cGMP-dependent kinase; (Munzel et al., 2003; 
Maruhashi et al., 2013). The elevations in NO at high altitude may well be an adaptive response 
to maintain circulatory homeostasis through both vasodilation and metabolic suppression  
[reviewed in: (Umbrello et al., 2013)]. 
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It is known that hypoxic-induced sympathoexcitation (Saito et al., 1988; Hansen & Sander, 
2003) may potentially modulate functional, and/or mechanical properties of large arteries via an 
increase in vasomotor tone (Hijmering et al., 2002; Dyson et al., 2006; Fok et al., 2012). To 
explore this possibility, we conducted a follow-up study in normobaric hypoxia to examine 
whether a similar reduction in FMD would occur in response to acute normobaric hypoxia, and 
the contributory role of increased sympathetic nerve activity via the α1-adrenoreceptor. Broadly 
consistent with our hypothesis, we found that FMD was markedly reduced in normobaric 
hypoxia (~28-35%). Moreover, following administration of the α1-blockade, these reductions in 
FMD were largely reversed back to normoxic baseline. Thus, our findings clearly support the 
notion that changes in FMD occur early within exposure to hypoxia and are under the influence 
of elevations in sympathetic nerve activity. We acknowledge that differences between 
normobaric and hypobaric hypoxia are possible, and the potential mechanism regulating the 
vascular response to shear stress may also differ. 
 
Arterial stiffness: Lowlanders experienced an 11% increase in central-PWV with high altitude 
exposure, with no change in peripheral-PWV. Carotid to femoral PWV is considered the non-
invasive gold standard measure of arterial stiffness (Laurent et al., 2006), and is influenced by 
the tone of arterial smooth muscle irrespective of the signalling pathway in which it is modulated 
(Fok et al., 2012). Vascular smooth muscle tone is affected by both endothelial cell signalling 
and the sympathetic nervous system (Wilkinson & McEniery, 2004; Bruno et al., 2012). As 
highlighted above, the FMD and GTN findings in the current study support impairment in 
endothelial function and increase in smooth muscle tone, both of which alone or in combination 
may explain our observed increase in central-PWV.  
 
It is important to note that the anatomy of arteries and the extent to which smooth muscle tone 
influences stiffness is not homogenous across the vascular tree, e.g., muscular arteries (radial) 
unlike elastic arteries (carotid) show little stiffening with ageing (Avolio et al., 1985; Stewart et 
al., 2003). Additionally, structural changes can be present without obvious functional changes 
and vice versa (Naghavi, 2009). The results of the current study support this concept. In support 
of arterial differences along the vascular tree with ambient hypoxia, our lowlander group 
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experienced a ~7% increase in CCA diameter at 5050 m, whereas brachial diameter was 
unchanged. Although the regional mechanisms are unknown, the differential effects of hypoxia 
on vessel dilation would seem of physiological benefit in that dilation of the CCA would act to 
redistribute blood flow towards the cerebral vessels to help maintain a normal oxygen flux to the 
brain in the face of arterial hypoxemia (Ainslie & Ogoh, 2010).  
 
Comparisons between lowlanders and highlanders: When compared to lowlanders at sea level, 
we provide evidence of impaired vascular function in highlanders, as indexed by ~20% reduction 
in FMD/ GTN and elevation in central-PWV of ~17%. Interestingly, these observed changes in 
vascular function and central-PWV in natives were remarkably comparable to lowlanders at 
5050 m. These comparable alterations in vascular function indicate that these changes might not 
be dependent on the time spent at high altitude. Compared to lowlanders at both sea level and 
high altitude, highlanders had a significantly lower (~19%) carotid wall: lumen ratio. This 
difference likely reflects the consistently lower CIMT and larger lumen diameter in the 
highlanders.  It is unclear if this difference is reflective of a beneficial adaptation high altitude, or 
the specific mechanism(s) governing this response; however, a smaller wall thickness and larger 
lumen diameter have been reported in individuals following chronic exercise exposure (Rowley 
et al., 2012). It has been suggested that exercise training induces an increase in shear stress and 
transmural pressure (Tuttle et al., 2001; Laughlin et al., 2008; Green et al., 2011); these 
collective changes can increase the circumferential strain placed on the blood vessel and 
stimulate structural arterial remodelling and an anti-atherogenic effect, resulting specifically in 
luminal expansion (Laughlin et al., 2008; Rowley et al., 2012). Although we do not provide 
evidence to support the above concept with high altitude exposure, the increase in carotid 
diameter in lowlanders with high altitude exposure may indicate that arterial remodelling is an 
adaptive response to high altitude.   
 
Perspectives  
The high-altitude induced changes in FMD/GTN dilation and central-PWV in lowlanders and the 
comparison with highlanders has potential clinical relevance. This is especially evidenced in 
native highlanders who have been reported to show earlier cardiovascular degeneration changes 
with aging, in particular arterial wall stiffening (Otsuka et al., 2005). It has been estimated that a 
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1% (absolute) decrease in FMD is associated with a 9% increase in cardiovascular risk  (Green et 
al., 2012); and a 1 m·s
-1
 increase in aortic stiffness (central-PWV) accounts for a 15% increase in 
cardiovascular and all-case mortality (Vlachopoulos et al., 2010). The absolute mean differences 
in FMD and central-PWV between highlanders at high altitude and lowlanders at sea level were 
1.6% and 1.0 m·s
-1
, respectively; and the absolute change in lowlanders upon exposure to high 
altitude from sea level was 0.9% and 0.7 m·s
-1
. These findings indicate that: 1) natives to high 
altitude are at greater risk of advanced vascular aging, due to impairment in endothelial and 
smooth muscle function; thus, lifelong adaption to high altitude does not appear to provide any 
functional cardioprotective benefits; and 2) the vascular alterations/adaptions in vascular 
endothelial and smooth muscle function with high-altitude exposure are significant enough to 
induce an increase in cardiovascular risk in healthy lowlanders. These findings may be 
particularly relevant to ‘at-risk’ populations who ascend to high altitude (e.g. patients with sleep 
apnoea, heart failure, lung disease, etc.). The potential risk and level of altitude required to 
induce adverse changes in vascular function remains to be established.  
Methodological considerations  
Due to the nature of high-altitude research, our sample size was relatively small. Nevertheless, 
clear significant differences were evident, indicating that additional numbers would be unlikely 
to alter our findings. An important consideration in the assessment of FMD in cross-sectional 
and longitudinal studies is that of consistency in the brachial baseline diameter and shear-stress 
stimulus and related normalisation (Atkinson et al., 2009; Green et al., 2012). Following ~2 
weeks at 5050 m, FMD was unaltered compared to initial arrival to high altitude. It is important 
to highlight that compared to initial exposure at 5050 m, the SR area under the curve stimulus 
influencing the FMD response was reduced by ~40% following the prolonged stay at 5050 m. 
Despite this marked reduction in shear stress, the FMD reduction was markedly consistent across 
time at high altitude. Whether or not these changes in SR area under the curve reflect a subtle 
functional improvement in vascular function is unclear. In addition, the changes in FMD 
persisted following allometric scaling to control for variability in baseline diameter.  
Although logistically difficult in field conditions or prolonged laboratory studies, complimentary 
measures of sympathetic nerve activity either via noradrenaline concentrations or muscle 
sympathetic nerve activity would have added to mechanistic interpretation to our findings. It is 
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also known that physical fitness influences the brachial baseline diameter and hence FMD 
response (Green et al., 2013). Although there were no significant differences in brachial baseline 
diameter between conditions (e.g., time at altitude) or groups (e.g., lowlanders vs. highlanders), 
complementary measures of cardiorespiratory fitness may have been useful.   
It has been reported that a linear relationship exists between central-PWV in elderly individuals 
with cardiovascular disease and HR when >70 beats∙min-1 (Lantelme et al., 2002). For example, 
a 6 beats∙min-1 increase in HR above 70 beats∙min-1 corresponds to a <0.3 m∙s-1 increase in 
central-PWV (Stewart et al., 2003). How relevant these findings are to an otherwise young, non-
cardiovascular-diseased population is currently unknown, and the translation to the current study 
is questionable given that the lowest central-PWV reported by Lantelme et al. (2002) at a HR of 
~60 beats∙min-1 was double that present in the current study in healthy lowlanders free of overt 
cardiovascular disease even when exposed to the vascular stress associated with high altitude. As 
anticipated, the peak HR in the current study occurred following acute exposure to 5050m (77 
beats∙min-1) and was reduced over 2-3 weeks to 73 beats∙min-1. Because the mean difference in 
central-PWV between sea level and acute-high altitude was 0.6 m∙s-1 (which persisted over time 
despite reductions in HR), it is possible that HR may have contributed up to half of the increase 
seen in central-PWV with acute-altitude exposure; however, given that the increase in central-
PWV persisted with chronic exposure, when HR had declined, it seem other mechanisms 
influenced the changes in central-PWV with high altitude. Additionally, we would have expected 
small changes in blood viscosity and haemoconcentration over 2 weeks at altitude (Lucas et al., 
2011), however, such changes would appear to have a negligible impact on vascular function 
measures including FMD, PWV and carotid compliance (Parkhurst et al., 2012); therefore, we 
feel that changes in blood viscosity are unlikely to explain our findings within or between 
groups.  
 
Although we provided some insight into the role of oxidative stress and NO as potential 
mechanisms of vascular dysfunction, we were unable to collect these blood markers in the high 
altitude natives. As such, we do not know if similar changes and relationships may also be 
evident in this group.  It is also important to acknowledge that evidence exists to indicate that 
highland groups with different evolutionary histories, e.g. Andean and Tibetan populations, 
differ from one another genetically, resulting in different adaptation responses to hypoxia (Beall, 
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2007; Bailey et al., 2013). Therefore, as Tibetan highlanders were selected in the current study, 
caution is needed when comparing or interpreting the results of the current study with Andean 
populations. Further research is needed to explore vascular function in different highland groups.  
 
Conclusion  
Our findings are the first to show that vascular function alterations in healthy lowlanders during 
high altitude exposure are potentially attributed to impairment in both endothelial and vascular 
smooth muscle function, associated with an increase in central arterial stiffness. The mechanisms 
underpinning the changes in vascular function with hypoxia seem to be related at least partly to 
elevations in oxidative stress and sympathetic nerve activity. It appears that the effects of 
ambient hypoxia on the vascular tree are not uniform, and that a lifetime of high altitude 
exposure neither exacerbates nor protects against the vascular function impairments seen 
following arrival to high altitude. In contrast, highland Sherpa had a consistently lower carotid 
wall: lumen ratio than did lowlanders at sea level and high altitude; these findings potentially 
indicate that arterial remodelling is an adaptive response to chronic high altitude. The extent to 
which these changes may potentially translate into an elevated cardiovascular risk remained to be 
determined.  
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Tables 
 
Table 1: The effect of high altitude (5050 m) on cardiovascular variables in lowlanders and comparison with highlanders.    
Group  Lowlanders    Highlanders 
Location/altitude duration Sea level Acute-HA Chronic-HA Lifelong-HA 
SBP (mm Hg) 118 ± 7 119 ± 9 115 ± 9 106 ± 16 
DBP (mm Hg) 77 ± 7 73 ± 9 72 ± 9 72 ± 10 
MAP (mm Hg) 94 ± 10 86 ± 8 87 ± 7 83 ± 11 ‡ 
HR (beats∙min-1) 56 ± 10 77 ± 15 * 73 ± 15 * 77 ± 11 ‡ 
SaO2 (%) 99 ± 1 81 ± 3 * 83 ± 4 * 83 ± 2 ‡ 
Carotid compliance cm
2
/mmHg 0.17 ± 0.04 0.22 ± 0.03 * 0.19 ± 0.04 0.22 ± 0.08 
Carotid distensibilty mmHg
−1
 0.006 ± 0.001 0.006 ± 0.002 0.005 ± 0.001 0.006 ± 0.003 
β stiffness 4.5 ± 1.2 4.2 ± 1.2 4.5 ± 0.7 4.8 ± 2.0 
Carotid pulse pressure (mm Hg) 37 ± 7 32 ± 6 34 ± 6 30 ± 11 ‡ 
FMD     
Baseline diameter (mm) 4.2 ± 0.5 4.2 ± 0.5 4.1 ± 0.5 4.6 ± 0.5 
Peak diameter (mm) 4.4 ± 0.5 4.5 ± 0.6 4.4 ± 0.5 4.9 ± 0.5 
Time to peak (s) 60 ± 24 62 ± 20 59 ± 16 68 ± 21 
SRAUC (AUC) 20327 ± 5401 22961 ± 9163 14802 ± 5306 † 24490 ± 7230 
36 
 
 
Allometrically corrected FMD (%) 7.9 ± 1.4 6.7 ± 1.4 7.3 ± 1.4 6.7 ± 2.1 
GTN     
Baseline diameter (mm) 4.2 ± 0.5 4.4 ± 0.6 4.2 ± 0.5 4.6 ± 0.7 
Peak diameter (mm) 4.9 ± 0.5 4.9 ± 0.6 4.9 ± 0.5 5.3 ± 0.7 
Time to peak (s) 365 ± 56 372 ± 104 338 ± 70 368 ± 46 
FMD:GTN ratio 0.49 ± 0.12 0.49 ± 0.15 0.50 ± 0.14 0.49 ± 0.13 
VD     
Baseline diameter (mm) 4.1 ± 0.4 4.0 ± 0.4     4.0 ± 0.5  
Peak diameter (mm) 4.6 ± 0.4 4.4 ± 0.4 4.5 ± 0.5  
Time to peak (s) 97 ± 32 90 ± 31 105 ± 36  
SRAUC (AUC) 61089 ± 45870 63078 ± 25056 51850 ± 21826  
 
Values expressed as mean ± SD. HA, high altitude; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial 
blood pressure; HR, heart rate; SaO2, arterial oxygen saturation; CIMT, carotid intima media thickness; FMD, flow mediated dilation; 
GTN, glyceryl trinitrate, VD, vasodilator capacity; shear rate area under the curve (SRAUC). Different probe placement between FMD 
and VD test due to distal and proximal cuff placement. * Lowlanders at acute (days 2-3) and chronic-high altitude (days 12-14) are 
significantly different from sea level, P<0.001; † Chronic-high altitude significantly different from acute-high altitude in lowlanders 
(P=0.03); ‡ Highlanders significantly different from lowlanders at sea level (P=0.04).)…………………………………………………
Table 2: Markers of oxidative stress and nitric oxide, at sea level and following acute (day 1) 
and chronic (7 days) exposure to high altitude in lowlanders. 
 
Metabolites Sea Level (n=11) Acute-HA (n=11) Chronic-HA (n=7) 
Lipid hydroperoxides (µM) 1.87 ± 0.46 2.20 ± 0.67 *  2.14 ± 0.75 † 
Nitrite (nM) 212 ± 77 283 ± 136 † 304 ± 57 † 
-tocopherol (µM) 16.83 ± 3.91 15.56 ± 5.21 14.25 ± 3.12 
γ-tocopherol (µM) 1.75 ± 0.86 2.37 ± 0.89 3.49 ± 2.32 
-carotene (µM) 0.154 ± 0.092 0.141 ± 0.093 0.135 ± 0.119 
β-carotene (µM) 0.465 ± 0.367 0.430 ± 0.404 0.320 ± 0.347 
Retinol (µM) 1.77 ± 0.44 1.61 ± 0.45* 1.75 ± 0.86 
Lycopene (µM) 1.00 ± 0.38 0.91 ± 0.45 1.14 ± 0.81 
Zexanthin (µM) 0.054 ± 0.025 0.056 ± 0.026 0.044 ± 0.014 
Lutein (µM) 0.199 ± 0.121 0.187 ± 0.136 0.357 ± 0.632 
β-cryptoxanthin (µM) 0.084 ± 0.038 0.071 ± 0.032 0.054 ± 0.027 
 
Values expressed as mean ± SD. HA, high altitude. * Acute-HA significant different from sea 
level (n=11, paired t-test: P≤0.03). † Acute- and chronic-HA significant different from sea level 
(n=7, one-way ANOVA: P≤0.05).
Table 3: The time course effect of normobaric hypoxia on cardiovascular variables and effect of α1-blockade.  
 Inspirate Normoxia  Hypoxia  Normoxia 
Time (min)  0 60 220 330 60 
SBP (mm Hg) Placebo 114 ± 11 121 ± 26 109 ± 9 109 ± 8 112 ± 13 
 α1-blockade 109 ± 8 111 ± 8 116 ± 17 108 ± 12 113 ± 7 
DBP (mm Hg) Placebo 76 ± 10 71 ± 10 70 ± 10 74 ± 9 74 ± 9 
 α1-blockade 72 ± 8 71 ± 10 72 ± 12 65 ± 12 70 ± 10 
MAP (mm Hg) Placebo 90 ± 9 88 ± 7 83 ± 8 86 ± 7  87 ± 9  
 α1-blockade 83 ± 10 ‡ 85 ± 9 79 ± 14 80 ± 8  84 ± 8  
HR (beats∙min-1) Placebo 59 ± 10 68 ± 15  72 ± 15  72 ± 15 *† 60 ± 14  
 α1-blockade 61 ± 9 66 ± 9  66 ± 8  77 ± 13 ‡  65 ± 10  
SaO2 (%) Placebo 96 ± 2 72 ± 5 *† 76 ± 7 *† 80 ± 4 *† 97 ± 1  
 α1-blockade 96 ± 1 79 ± 7  81 ± 6  79 ± 7  97 ± 1  
FMD 
      
Baseline diameter (mm) Placebo 4.5 ± 0.4 4.5 ± 0.5 4.7 ± 0.6 † 4.5 ± 0.5 4.3 ± 0.5 
 α1-blockade 4.4 ± 0.5 4.5 ± 0.6 4.5 ± 0.4  4.6 ± 0.6 4.4 ± 0.5 
Peak diameter (mm) Placebo 4.8 ± 0.5 4.8 ± 0.6 4.8 ± 0.5 4.7 ± 0.5 4.6 ± 0.5 
 α1-blockade 4.7 ± 0.5 4.7 ± 0.6 4.8 ± 0.4 4.9 ± 0.6 4.8 ± 0.5 
Time to peak (s) Placebo 49 ± 17 46 ± 18 47 ± 20 54 ± 23 45 ± 12 
 α1-blockade 56 ± 21 50 ± 18 54 ± 25 61 ± 23 54 ± 18 
SRAUC (AUC) Placebo 22727 ± 6813 17847 ± 7468 20745 ± 13011  20142 ± 11799 22543 ± 6110 
 α1-blockade 23423 ± 11423 21498 ± 9124 22464 ± 11424  24043 ± 10701 25234 ± 11027 
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Values expressed as mean ± SD. SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial blood pressure; HR, 
heart rate; SaO2, arterial oxygen saturation; FMD, flow mediated dilation; SRAUC, shear rate area under the curve. * Significantly 
different from normoxia 0 min (baseline) in the placebo trial only. † Significantly different from normoxia 60 (recovery) in the 
placebo trial only (P≤0.001). ‡ Measurement time point in the α1-blockade trial significantly different from placebo trial (P≤0.03). 
Placebo vs. blockade at hypoxic time points 60 min and 120 min, n =10.  
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Figure 1: Schematic detailing experimental schedule for lowlander in study 1 (A) and study 2 
(B). In study A, measures were completed at sea level, upon initial arrival at high altitude (5050 
m; day 3) and following 12-14 days of partial acclimatisation at 5050 m.  In the follow-up study 
B, measures were completed in normoxia, prior to a 6 hr exposure of normobaric hypoxia 
(FIO2=0.11). Measures were repeated following 60 min, 210 min 330 min of hypoxia.  
Following 240 min of hypoxia (90 min prior to the last assessment in hypoxia [330 min]), 
participants orally consumed the α1-adrenoreceptor blocker, prazosin (1 mg/20 kg body mass) or 
placebo capsule. All measures were repeated in normoxia 60 min following the hypoxic 
exposure. 
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Figure 2: Illustration of ultrasound images and analysis techniques for: A, brachial flow 
mediated dilation (custom-designed edge-detection and wall-tracking software was used to 
obtain simultaneous measure of diameter and flow). B, beat-to-beat common carotid diameter 
(custom-designed edge-detection and wall-tracking software was used to obtain beat-to-beat 
diameter). C, common carotid intima-media thickness (CIMT: commercial edge-detection 
software (EchoPAC PC, GE Healthcare) was used to measure CIMT across consecutive cardiac 
cycles). 
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Figure 3: Carotid intima-medial thickness (IMT), carotid systolic and diastolic diameter, and 
carotid wall: lumen ratio in lowlanders at sea level (SL), acute-high altitude (A-HA) and 
following chronic-high altitude (C-HA), and comparison to highlanders at high altitude (5050 
m). * Significantly different from sea level (P≤0.02). † ‡ § Highlanders were significantly 
different from lowlanders at sea level, acute-high altitude and chronic-high altitude, respectively 
(P≤0.04). 
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Figure 4: Central and peripheral pulse wave velocity (PWV) in lowlanders at sea level (SL), 
acute-high altitude (A-HA) and following chronic-high altitude (P-HA), and with comparison to 
highlanders at high altitude (5050 m). * Significantly different from sea level (P≤0.04). † 
Highlanders significantly different from lowlanders at sea level (P=0.05). 
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Figure 5: Brachial flow mediated dilation (FMD), vasodilator capacity (VD) and glyceryl 
trinitrate (GTN) in lowlanders at sea level (SL), acute-high altitude (A-HA) and following 
chronic-high altitude (C-HA), and with comparison to highlanders at 5050 m. * Significantly 
different from sea level (P≤0.02). 
 
 
 
 
45 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Changes in flow mediated dilation (FMD) during normobaric hypoxia and the effect of 
α1-blockade. * Significantly different from normoxia 0 min (baseline) in the placebo trial only. † 
Normoxia 60 (recovery) significantly different from hypoxic measures in the placebo trial only 
(P≤0.001). ‡ Measurement at 330 min time point in the α1-blockade trial significantly different 
from placebo trial (P≤0.03). 
 
 
